Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity-Reference-Cited by-同舟云学术

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Published:2023-09-21 Issue:12 Volume:389 Page:1069-1084
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Kosiborod Mikhail N.¹,Abildstrøm Steen Z.¹,Borlaug Barry A.¹,Butler Javed¹,Rasmussen Søren¹,Davies Melanie¹,Hovingh G. Kees¹,Kitzman Dalane W.¹,Lindegaard Marie L.¹,Møller Daniél V.¹,Shah Sanjiv J.¹,Treppendahl Marianne B.¹,Verma Subodh¹,Abhayaratna Walter¹,Ahmed Fozia Z.¹,Chopra Vijay¹,Ezekowitz Justin¹,Fu Michael¹,Ito Hiroshi¹,Lelonek Małgorzata¹,Melenovsky Vojtech¹,Merkely Bela¹^ORCID,Núñez Julio¹^ORCID,Perna Eduardo¹^ORCID,Schou Morten¹,Senni Michele¹,Sharma Kavita¹,Van der Meer Peter¹,von Lewinski Dirk¹,Wolf Dennis¹,Petrie Mark C¹

Affiliation:

1. From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the...

Funder

Novo Nordisk

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2306963

Reference40 articles.

1. Epidemiology of Heart Failure

2. Heart Failure With Preserved Ejection Fraction

3. Evaluation and management of heart failure with preserved ejection fraction